PMID- 31981862 OWN - NLM STAT- MEDLINE DCOM- 20201113 LR - 20201113 IS - 1532-2688 (Electronic) IS - 1059-1311 (Linking) VI - 75 DP - 2020 Feb TI - Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. PG - 121-128 LID - S1059-1311(19)30781-2 [pii] LID - 10.1016/j.seizure.2019.12.022 [doi] AB - PURPOSE: To assess the efficacy, safety and tolerability of eslicarbazepine acetate (ESL) in patients transitioning from carbamazepine or oxcarbazepine to ESL in clinical practice, by analysing data from the Euro-Esli study. METHODS: Euro-Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments included responder rate (>/=50 % seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit), assessed after 3, 6 and 12 months of ESL treatment, and at the last visit. Safety and tolerability were assessed throughout follow-up by evaluating adverse events (AEs) and ESL discontinuation due to AEs, respectively. Data were analysed for cohorts of patients who transitioned from carbamazepine and oxcarbazepine to ESL either due to lack of efficacy or poor tolerability. RESULTS: Euro-Esli included 2058 patients, of whom 233 (11.3 %) transitioned from carbamazepine to ESL and 134 (6.5 %) transitioned from oxcarbazepine to ESL. After 12 months of ESL treatment, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n = 163) were 70.0 % and 30.9 %, respectively. Corresponding values for patients transitioning from oxcarbazepine due to lack of efficacy (n = 90) were 57.1 % and 25.0 %, respectively. Among patients who transitioned from carbamazepine and oxcarbazepine to ESL due to poor tolerability (n = 64 and n = 61, respectively), 26.6 % and 39.5 % experienced AEs, and 8.3 % and 6.8 % discontinued ESL due to AEs, respectively. CONCLUSION: ESL was efficacious and generally well tolerated in patients transitioning from carbamazepine or oxcarbazepine in clinical practice due to inadequate seizure control or intolerable AEs with these agents. CI - Copyright (c) 2019. Published by Elsevier Ltd. FAU - Rocamora, Rodrigo AU - Rocamora R AD - Epilepsy Monitoring Unit, Department of Neurology, Hospital Del Mar-Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Electronic address: rrocamora@parcdesalutmar.cat. FAU - Peltola, Jukka AU - Peltola J AD - Department of Neurology, Tampere University and Tampere University Hospital, Tampere, Finland. Electronic address: jukka.peltola@pshp.fi. FAU - Assenza, Giovanni AU - Assenza G AD - Universita Campus Bio-Medico di Roma, Rome, Italy. Electronic address: g.assenza@unicampus.it. FAU - McMurray, Rob AU - McMurray R AD - Eisai Europe Ltd, Hatfield, Hertfordshire, UK. Electronic address: Rob_McMurray@eisai.net. FAU - Villanueva, Vicente AU - Villanueva V AD - Hospital Universitario y Politecnico La Fe, Valencia, Spain. Electronic address: villanueva_vichab@gva.es. LA - eng PT - Journal Article DEP - 20191223 PL - England TA - Seizure JT - Seizure JID - 9306979 RN - 0 (Anticonvulsants) RN - 0 (Dibenzazepines) RN - 33CM23913M (Carbamazepine) RN - BEA68ZVB2K (eslicarbazepine acetate) RN - VZI5B1W380 (Oxcarbazepine) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anticonvulsants/adverse effects/*pharmacology MH - Carbamazepine/adverse effects/*pharmacology MH - Clinical Studies as Topic MH - Dibenzazepines/adverse effects/*pharmacology MH - Drug Substitution MH - *Drug-Related Side Effects and Adverse Reactions MH - Europe MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Outcome Assessment, Health Care/*statistics & numerical data MH - Oxcarbazepine/adverse effects/*pharmacology MH - Young Adult OTO - NOTNLM OT - Carbamazepine OT - Clinical practice OT - Epilepsy OT - Eslicarbazepine acetate OT - Euro-Esli OT - Oxcarbazepine COIS- Declaration of Competing Interest RR is a consultant for Eisai, Bial, UCB, GlaxoSmithKline and Shire, and receives grant and research support from Bial, Eisai, and UCB. JP has participated in clinical trials for Eisai, UCB, and Bial; received research grants from Eisai, Medtronic, UCB, and Cyberonics; received speaker honoraria from Cyberonics, Eisai, Medtronic, Orion Pharma, and UCB; received support for travel to congresses from Cyberonics, Eisai, Medtronic, and UCB; and participated in advisory boards for Cyberonics, Eisai, Medtronic, UCB, and Pfizer. GA has no conflicts of interest. RM is a current employee of Eisai Europe Ltd. VV has participated in advisory boards and pharmaceutical industry-sponsored symposia for Eisai, UCB Pharma, Bial, Pfizer, GSK, Esteve, Novartis and GW Pharma. EDAT- 2020/01/26 06:00 MHDA- 2020/11/18 06:00 CRDT- 2020/01/26 06:00 PHST- 2019/11/15 00:00 [received] PHST- 2019/12/19 00:00 [revised] PHST- 2019/12/21 00:00 [accepted] PHST- 2020/01/26 06:00 [pubmed] PHST- 2020/11/18 06:00 [medline] PHST- 2020/01/26 06:00 [entrez] AID - S1059-1311(19)30781-2 [pii] AID - 10.1016/j.seizure.2019.12.022 [doi] PST - ppublish SO - Seizure. 2020 Feb;75:121-128. doi: 10.1016/j.seizure.2019.12.022. Epub 2019 Dec 23.